Lianna Orlando, PhD

Title: Senior Director of Research

Organization: CureDuchenne

Bio: Lianna Orlando, PhD, is CureDuchenne’s Senior Director of Research, where she helps identify and evaluate strategic investments aimed at developing treatments for Duchenne Muscular Dystrophy. Prior to CureDuchenne, Lianna was at the Muscular Dystrophy Association (MDA), where she oversaw basic, translational, and clinical grant programs, including MDA’s venture philanthropy program, and Fidelity Biosciences Research Initiative (FBRI), focusing on funding research programs in neurodegenerative diseases. Before leaving academia, Lianna was a junior faculty member in the Neurology Department at Massachusetts General Hospital. She completed her doctorate in Neurobiology from Harvard University, and a select master’s degree in Medicine from Harvard Medical School. She has taught both undergraduates and medical students at Harvard, and worked as a freelance science writer for disease foundations and scientific journals. She holds B.S. degrees in Chemistry and in Magazine Journalism from Syracuse University (Summa Cum Laude/Phi Beta Kappa).

2021 FUTURES: Exon Skipping Panel

Information and updates on exon skipping therapies and research from experts in the Duchenne community.

Ash Dugar, PhD

Senior Vice President, Medical Affairs

Dyne Therapeutics

Kevin Eggan, PhD

Group Vice President, Head of Research and Early Development


Leslie Magnus, MD

Vice President, Medical Affairs

NS Pharma

James McArthur, PhD

President and Chief Executive Officer


Lianna Orlando, PhD

Senior Director of Research


Mark Stahl, MD, PhD

Senior Medical Director, Clinical Development

Avidity Biosciences

Deanna Tucker, PharmD

Senior Medical Science Liaison

Sarepta Therapeutics

2024 FUTURES – Therapies to Preserve and Protect Muscle

Presentations covering therapies aiming to preserve and protect muscle in Duchenne, including anti-inflammatory agents, muscle stabilizers, and other mechanisms with relevant updates from companies in the space.


Karyn Koladicz, MD

Executive Medical Director for Medical Affairs, Neurology PTC Therapeutics

Lianna Orlando, PhD

Senior Director of Research


Abby Bronson

Vice President, Patient Advocacy & External Innovation

Edgewise Therapeutics

Stanley Iyadurai, MD, PhD

Sr VP Medical Affairs and Drug Discovery


Scott Baver, PhD

Head of Medical Affairs

ITF Therapeutics

Mark Awadalla

Vice President of Clinical Operations


2024 FUTURES Exon skipping

A brief introduction on the rationale behind exon skipping therapies, followed by an overview of current and investigative exon skipping therapies.
Key insights were shared by Dr. Angel Angelov, Dr. Ash Dugar, Lianna Orlando, PhD, Dr. Kevin M. Flanigan, Laura Torrente, PhD, Alayna Tress, MPH, Karin Lucas, PhD, Mahasweta Girgenrath, Phd, Jessica Duis, MD, Husam Younis, PharmD, PhD.

Lianna Orlando, PhD

Senior Director of Research


Ash Dugar, PhD

Senior Vice President, Medical Affairs

Dyne Therapeutics

Kevin Flanigan, MD

Director, Center for Gene Therapy Nationwide Children's Hospital

Karin Lucas, Ph.D

West Medical Science Liaison Team Lead, Global Medical Affairs Sarepta Therapeutics

Laura Torrente, PhD

Alayna Tress, MPH

Mahasweta Girgenrath, Phd

Jessica Duis, MD

Husam Younis, PhD

Dr. Angel Angelov

2024 FUTURES New Therapeutic Approaches to Address Unmet Needs

Presentations on early-stage research and development companies working on approaches to address the unmet therapeutic needs in the Duchenne community.

Sharif Tabebordbar, PhD

Lianna Orlando, PhD

Courtney Young, PhD